Thomas Schwaab

Thomas Schwaab

MD, PhD

Specializing In:

Bladder cancer Kidney cancer Prostate cancer Testicular cancer Partial nephrectomy Robotic kidney surgery Retroperitoneal surgery IVC surgery advanced in kidney cancers

Special Interests:

Role for partial nephrectomy Immunotherapy for bladder, prostate and kidney cancers Robotic simulation

About Me

Biography:

Thomas Schwaab, MD, PhD, is Roswell Park's Chief of Strategy, Business Development and Outreach. Dr. Schwaab is also a Professor of Oncology and Immunology, and joined the Institute’s faculty in 2009.

In his new role, Dr. Schwaab supervises Roswell’s business development and overall strategic development. He assures that business and clinical initiatives are delivered appropriately and support maximal quality, efficiency and effectiveness, and works to continually widen the Institute’s scope of operations and growth potential at national and international levels.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Chief of Strategy, Business Development and Outreach
  • Professor of Oncology
  • Department of Urology
  • Department of Immunology
  • CEO, RPCI Oncology, PC
Global Biotechnology and Cancer Therapeutics
  • Chief Executive Officer

Background

Education and Training:

  • MD - Medizinische Hochscule Hannover, Hannover, Germany
  • PhD - Medizinische Hochscule Hannover, Hannover, Germany

Residency:

  • Klinikum Lippe-Detmold, Detmold, Germany
  • Dartmouth-Hitchcock Medical Center, Lebanon, NH

Fellowship:

  • Tumor Immunotherapy Program, Dartmouth College, Hanover, NH

Board Certification:

  • Urology, American Board of Urology

Publications

  • Brewer K, O'Malley RL, Hayn M, Safwat MW, Kim H, Underwood W 3rd, Schwaab T. Perioperative and renal function outcomes of minimally invasive partial nephrectomy for t(1b) and t(2a) kidney tumors.Journal of endourology 2012; 263:244-248
  • O'Malley RL, Hayn MH, Hellenthal NJ, Kim HL, Underwood W 3rd, Schwaab T. Safety and outcomes of surgical treatment of renal cell carcinoma in the elderly. Canadian journal of urology 2012; 191:6111-6117
  • O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W 3rd, Pili R, Schwaab T. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? . Urology 2011; 783:595-600
  • Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T. Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care. Journal of urology 2011; 1852:415-420
  • Hayn MH, Schwaab T, Underwood W, Kim HL. RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. BJU international 2011; 1086:876-881
  • Schwaab T, Ernstoff MS. Therapeutic vaccines in renal cell carcinoma. Therapy 2011; 48:369-377
  • Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth Jr RJ, Heaney JA, Noelle RJ, Ernstoff MS. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clinical cancer research 2009; 1515:4986-4992
  • Schwaab M, Hansen S, Gurr A, Schwaab T, Minovi A, Sudhoff H, Dazert S. Protein isolation from ear wax made easy. European archives of oto-rhino-laryngology 2009; 26611:1699-1702

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about their care and leave your own review.

Leave a Review